2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 388-390
Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

1056 Armored TmCD19-IL18 CAR T cells in patients with CD19+ lymphomas

Jakub Svoboda, MD, Daniel Landsburg, MD2, Elise A. Chong, MD3, Sunita Dwivedy Nasta, MD, MS4, Michael R Cook, MD5, Stefan K Barta, MD6, Jordan S Carter, MD7, Colin J. Thomas, MD8, Emily B. Tomasulo, DO9, Noelle Frey, MD, MSCE10, Joanne Shea11, Charles W. Tongue12, Jean McConville13, Rutendo Manyeka14, Megan Four15, Amy Marshall16, Anne Chew17, Rachel Leskowitz18, Shannon Christensen, PhD19, Vanessa Gonzalez20, Joseph Fraietta, PhD21, Marco Ruella, MD22, Julie Jadlowsky23, Gabriela Plesa, MD, PhD24, Juliana Rojas Levine25, Donald Hasenmayer26, Don Siegel, MD PhD27, Bruce L Levine, PhD28, David Porter, MD29, Wei-Ting Hwang, PhD30, Stephen J Schuster31, Elizabeth Hexner, MD32, Carl H. June Jr, MD33
1 University of Pennsylvania, Philadelphia, United States
2 University of Pennsylvania, Philadelphia, United States
3 University of Pennsylvania, Philadelphia, United States
4 University of Pennsylvania, Philadelphia, United States
5 University of Pennsylvania, Philadelphia, United States
6 University of Pennsylvania, Philadelphia, United States
7 University of Pennsylvania, Philadelphia, United States
8 University of Pennsylvania, Philadelphia, United States
9 University of Pennsylvania, Philadelphia, United States
10 University of Pennsylvania, Philadelphia, United States
11 University of Pennsylvania, Philadelphia, United States
12 University of Pennsylvania, Philadelphia, United States
13 University of Pennsylvania, Philadelphia, United States
14 University of Pennsylvania, Philadelphia, United States
15 University of Pennsylvania, Philadelphia, United States
16 University of Pennsylvania, Philadelphia, United States
17 University of Pennsylvania, Philadelphia, United States
18 University of Pennsylvania, Philadelphia, United States
19 University of Pennsylvania, Philadelphia, United States
20 University of Pennsylvania, Philadelphia, United States
21 University of Pennsylvania, Philadelphia, United States
22 University of Pennsylvania, Philadelphia, United States
23 University of Pennsylvania, Philadelphia, United States
24 University of Pennsylvania, Philadelphia, United States
25 University of Pennsylvania, Philadelphia, United States
26 University of Pennsylvania, Philadelphia, United States
27 University of Pennsylvania, Philadelphia, United States
28 University of Pennsylvania, Philadelphia, United States
29 University of Pennsylvania, Philadelphia, United States
30 University of Pennsylvania, Philadelphia, United States
31 University of Pennsylvania, Philadelphia, United States
32 University of Pennsylvania, Philadelphia, United States
33 University of Pennsylvania, Philadelphia, United States

Introduction: Armored CAR T cells that secrete interleukin-18 (huCART19-IL18) demonstrated durable activity in patients with relapsed CD19+ lymphomas after previous anti-CD19 CAR T-cell failure (Svoboda et al, NEJM 2025). Expansion of huCART19-IL18 and clinical responses appeared higher in patients who had previously received products with a CD28 rather than a 4-1BB costimulatory domain, although the mechanism remains unclear. We next developed TmCD19-IL18, a similar autologous CD19-directed 4-1BB CAR T-cell product that constitutively secretes IL18 but contains a novel anti-CD19 binder.

Methods: We conducted a single-institution, investigator-initiated phase I trial of TmCD19-IL18 in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma (NCT05989204). Following apheresis, a 3-day manufacturing process was used to transduce T cells with a lentiviral vector co-expressing a humanized anti-CD19 chimeric antigen receptor and IL18. Bridging therapy was permitted. Lymphodepletion (LD) consisted of either bendamustine (90 mg/m² daily for 2 days) or cyclophosphamide (Cy) (250 mg/m²) plus fludarabine (Flu) (25 mg/m²) daily for 3 days. TmCD19-IL18 cells were administered as a single intravenous infusion. A standard 3+3 dose-escalation design was used to determine the recommended dose for expansion (RDE), with a starting dose level (DL) of 7x10⁶ CAR-positive cells. Responses were assessed per Lugano criteria. The primary objective was safety; secondary objectives included manufacturing feasibility and efficacy; additional correlative studies included T-cell persistence and cytokine analyses.

Results: As of June 10, 2026, 22 patients are enrolled. Two patients are awaiting infusion, 2 opted for alternative therapies, and 2 became ineligible before infusion (1 due to rapid progression, 1 due to diagnosis of another malignancy). A total of 16 patients received TmCD19-IL18 and were evaluable for safety and efficacy: 12 (75%) were male, 9 (56%) had large B-cell lymphoma, 4 (25%) mantle cell lymphoma, 2 (13%) follicular lymphoma, and 1 (6%) marginal zone lymphomas. The median age was 61 years (range, 34-73). The median number of prior therapies was 6 (range, 4-9). Fifteen (94%) had received prior commercial anti-CD19 CAR therapy including 8 (53%) with a 4-1BB product and 7 (47%) with a CD28 product. Bridging was used in 14 (88%) patients. All products were successfully manufactured at the assigned DL. LD therapy included bendamustine in 14 (88%) and Cy/Flu in 2 (12%). No treatment-related deaths or unexpected toxicities occurred. Ten patients (63%) experienced cytokine release syndrome (CRS) that was mild or moderate: 7 grade (G) 1 and 3 G2. The median time to CRS event was 7 days (range, 4-12) and median duration was 5 days (range, 2-12). Three (19%) developed immune effector cell-associated neurotoxicity syndrome (ICANS): 2 G3 and 1 G4. The median time to ICANS was 12 days (range, 9-12) and the median duration was 3 days (range, 3-4). Two of the severe ICANS events occurred in the first 3 patients at DL1, meeting DLT criteria and prompting de-escalation to DL-1 (2x10⁶ cells). No DLTs occurred at DL-1. Six patients were subsequently treated at DL1a (5x10⁶ cells), and 1 grade 3 ICANS event was observed. DL1a was selected as the RDE; 1 additional patient has been treated in the expansion phase of the study. The overall response rate for all patients was 81% (95%CI: 54-95) with 10 (63%) achieving a complete response and 3 (19%) a partial response. Response rates did not differ by prior CAR T-cell type (p>0.9). Median duration of response was 5 months (95%CI: 2-NE). With median follow-up of 12 months (range, 3-26), the median progression-free survival (PFS) was 3 months (95%CI: 1-NE) with 6-month PFS of 37% (95%CI: 13-62). The median overall survival (OS) was not reached (95%CI: 10-NE) with 6-month OS of 85% (95%CI: 51-96). There was no significant difference in peak expansion of TmCD19-IL18 based on prior CAR T-cell type exposure.

Conclusions: Armoring CD19-directed CAR T cells with IL18 produced a high response rate in lymphoma patients progressing after prior commercial CAR T-cell therapy. TmCD19-IL18 cells have had manageable toxicity at the recommended dose for expansion of 5x10⁶ CAR-positive cells. Although patient numbers remain small, the novel CD19 binder may mitigate the lower peak expansion and response rates previously observed with huCART19-IL18 among patients exposed to prior 4-1BB–based CAR T-cell products.

Jakub Svoboda, MD: AstraZeneca - Research Funding; Kite, a Gilead Company - Research Funding; Pharmacyclics - Research Funding; Merck - Research Funding; Incyte - Research Funding; BMS - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); Abbvie/Genentech - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Atara Biotherapeutics - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)